Monday, July 26, 2021
HomeLatest Pharma-NewsSurVaxM: A novel anti-cancer immunotherapy for the treatment of glioblastoma brain cancers

SurVaxM: A novel anti-cancer immunotherapy for the treatment of glioblastoma brain cancers

Nov 15, 2019: Shanghai Fosun Pharmaceutical and MimiVax LLC have entered into a China-exclusive licensing agreement for the clinical development and commercialization of SurVaxM.

SurVaxM is first-in-class, patented peptide immunogen targeting Survivin Antigen on tumor cells, a novel anti-cancer immunotherapy in the treatment of newly diagnosed glioblastoma brain cancers.

- Advertisement -

Glioblastoma is an adult-common malignant neuroepithelial neoplasm in the central nervous system, the tumor has a fast growth rate, with 70-80% of patients surviving a disease course of only 3 to 6 months ( most devastating type in the WHO  classification  of central nervous system tumors).  

Presently, patient’s survival time is in the range of 14.5 to 16.6 months when treated with surgery, radiotherapy, chemotherapy and other supportive therapy.SurVaxM stimulates the production T-cell and B cell immunity simultaneously with unique cellular and antibody-mediated anti-tumor responses.

https://www.fosunpharma.com/en/news/news-details-3786.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

five × 2 =

- Advertisment -

Most Popular